Pharmaceutical giant Zeneca has hired Lowe Fusion Healthcare to
develop PR programmes for two cancer drugs after it impressed the
company with its work on Accolate, an anti-asthma drug launched in the
UK last week.
Lowe Fusion has won the contract to handle UK and international PR for
Tomudex, a colorectal cancer drug, and the UK account for Arimidex, a
breast cancer drug.
Neil Kendle, Lowe Fusion chairman, said the contracts did not specify an
end date and that Lowe Fusion is already discussing next year’s work
Duncan Burke, professional relations and PR manager at Zeneca, said the
quality of Lowe Fusion’s strategic thinking and day to day work over
several years on Accolate helped it win the other Zeneca work.
The UK accounts for Arimidex and Tomudex will involve media relations
work with the medical and consumer press, and also opinion leader
This involves identifying key opinion formers, ensuring they know
Zeneca’s products and delivering their views on cancer treatments to
general and medical audiences.